A Smart + Strong Site
Subscribe to:
POZ magazine

Back to home » Treatment News » Top Stories

Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
FDA Approves New Single-Tablet HIV Regimen, Triumeq
Life Expectancy for Young People With HIV Is Nearly Normal
A 15-Year Jump in Life Expectancy for People With HIV
Scientists Devise Method of Snipping HIV From Immune Cells
Monkey HIV Vaccine Success Opens Door for Human Trials
HIV Combo Pill Less Toxic Thanks to New Form of Tenofovir
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


September 1, 2011

Crushed Kaletra Tablets Not Recommend for Children Living With HIV

Crushing Kaletra (lopinavir/ritonavir) tablets to make the medication easier to take by children should be avoided, according to a new paper published ahead of print by the Journal of Acquired Immune Deficiency Syndromes.

Kaletra is widely recommended as a first-line treatment option for infants, children and adolescents living with HIV.

Unfortunately, the tablet version of Kaletra—used by most adults living with HIV—is a common barrier to pediatric antiretroviral therapy. Swallowing tablets can be challenging in school-aged children and adolescents, and it may represent a choking hazard in younger pediatric patients. “Children under 7 years of age,” writes Brookie Best, PharmD, of the University of California at San Diego, and her colleagues, “are frequently unable to swallow even smaller tablets.”

A liquid version of the drug is available. However, according to the authors, “[t]he liquid formulation has an extremely unpleasant taste with a high content (42 percent) of alcohol, creating the potential for significant alcohol toxicity with overdose, especially in infants.” It must also be taken with food and requires refrigeration, which limits its use in resource-poor settings.

When the liquid formulation isn’t feasible and pill-swallowing difficulties arise, Best and her colleagues note, caregivers often consider dosing children with broken or crushed tablets.

This practice comes with risks, however. Breaking or crushing tablets may result in too little drug passing into the bloodstream, potentially increasing the risk of drug resistance and treatment failure. But until now, no studies involving human subjects have been conducted to assess this risk.

The study conducted by Best and her colleagues evaluated 12 children living with HIV, ages 10 to 16 years old, who had drug levels checked seven times during a 12-hour period after taking either a Kaletra tablet or one that had be crushed by a pharmacist. 

Among the youth who took a crushed tablet, lopinavir levels—determined using a measurement called area under the curve (AUC)—were 45 percent below those achieved using the intact tablets. Similarly, their ritonavir levels were 47 percent below what they should have been. 

The researchers noted, however, that the magnitude of the blood level reductions after taking crushed Kaletra “was highly variable and unpredictable between subjects, ranging from 5 to 75 percent reduction in AUC.”

“Increased doses and therapeutic drug monitoring are needed to ensure adequate Kaletra exposure in patients requiring crushed Kaletra tablets,” the authors conclude. “The reduced exposure with crushed Kaletra tablet dosing reinforces the need to discourage this dosing practice.”

Search: Kaletra, lopinavir, ritonavir, tablets, crushed, pediatrics, children, dosing, pharmacokinetics, AUC

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Quick Links
About HIV and AIDS
The Cure
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Conference Coverage
Health Services Directory
POZ Magazine
AIDSmeds on Twitter

Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014

21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014

7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013

more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.